Timolol Maleate Ophthalmic Gel Forming Solution, 
0.25% and 0.5%

Sterile Ophthalmic Gel Forming Solution

DESCRIPTION

Timolol maleate ophthalmic gel forming solution is a non-selective beta-adrenergic receptor blocking agent. Its chemical name is (−)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levorotatory. The nominal optical rotation of timolol maleate is:

\[ [\alpha]_{25^\circ} \text{ in } 0.1N \text{ HCl (C=5\%)} = -12.2^\circ. \]

405 nm

Its molecular formula is \( \text{C}_{13}\text{H}_{26}\text{N}_{4}\text{O}_{3}\text{S} \cdot \text{C}_{4}\text{H}_{8}\text{O}_{4} \) and its structural formula is:

![Structural formula of timolol maleate](image)

Timolol maleate has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol.

Timolol maleate ophthalmic gel forming solution is supplied as a sterile, isotonic, buffered, aqueous solution of timolol maleate in two dosage strengths. Each mL of timolol maleate ophthalmic gel forming solution 0.25% contains 2.5 mg of timolol (3.4 mg of timolol maleate). Each mL of timolol maleate ophthalmic gel forming solution 0.5% contains 5.0 mg of timolol (6.8 mg of timolol maleate). Inactive ingredients: xanthan gum, tromethamine, boric acid, mannitol, polysorbate-80, and purified water. Preservative: benzododecinium bromide 0.012%.

Xanthan gum is a purified high molecular weight polysaccharide gum produced from the fermentation by bacterium *Xanthomonas campestris*. An aqueous solution of xanthan gum, in the presence of tear protein (lysozyme), forms a gel. Upon contact with the precorneal tear film, timolol maleate ophthalmic gel forming solution forms a gel that is subsequently removed by the flow of tears.
CLINICAL PHARMACOLOGY

Mechanism of Action

Timolol maleate is a beta₁ and beta₂ (non-selective) adrenergic receptor-blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity.

Timolol maleate ophthalmic gel forming solution, when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage.

The precise mechanism of the ocular hypotensive action of timolol maleate ophthalmic gel forming solution is not clearly established at this time. Tonography and fluorophotometry studies of timolol maleate ophthalmic solution in man suggest that its predominant action may be related to reduced aqueous formation. However, in some studies, a slight increase in outflow facility was also observed.

Beta-adrenergic receptor blockade reduces cardiac output in both healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function beta-adrenergic receptor blockade may inhibit the stimulatory effect of the sympathetic nervous system necessary to maintain adequate cardiac function.

Beta-adrenergic receptor blockade in the bronchi and bronchioles results in increased airway resistance from unopposed parasympathetic activities. Such an effect in patients with asthma or other bronchospastic conditions is potentially dangerous.

Pharmacokinetics

Following topical ocular administration of timolol to humans, low concentrations of drug are found in plasma. After bilateral administration of a 0.5% timolol maleate solution to healthy volunteers, maximum plasma concentrations were generally below 5 ng/mL. Pharmacokinetic studies in humans using this gel forming solution formulation were not performed. However, systemic uptake from a gel matrix is expected to be slower than from a non-gel forming solution based on studies using other gel forming solutions. The maximum plasma timolol concentrations from the gel forming drop is not expected to exceed those of the 0.5% timolol maleate solution.
Clinical Studies
In controlled, double-masked, multicenter clinical studies, timolol maleate ophthalmic gel forming solution administered once daily was compared to equivalent concentrations of TIMOPTIC® (timolol maleate ophthalmic solution) [Merck and Co., Inc.] administered twice daily. Timolol maleate ophthalmic gel forming solution once daily was shown to be equally effective in lowering intraocular pressure as the equivalent concentration of TIMOPTIC administered twice daily. The effect of timolol in lowering intraocular pressure was evident for 24 hours with a single dose of timolol maleate ophthalmic gel forming solution. Repeated observations over a three-month study period indicate that the intraocular pressure-lowering effect of timolol maleate ophthalmic gel forming solution was consistent. The results from the clinical trials are shown in the following figures.

Mean IOP and Std Dev (mmHg) by Treatment Group

**Timolol Maleate Ophthalmic Gel Forming Solution 0.25% Study**

---
Timolol Maleate Ophthalmic Gel Forming Solution 0.25% q.d. n = 151

---
TIMOPTIC 0.25% b.i.d. n = 152

---

October 13, 1998
Timolol maleate ophthalmic gel forming solution administered once daily had a safety profile similar to that of an equivalent concentration of TIMOPTIC administered twice daily. Due to the physical characteristics of the formulation, transient blurred vision was reported more frequently in patients administered timolol maleate ophthalmic gel forming solution. (See ADVERSE REACTIONS.)

Timolol maleate ophthalmic gel forming solution has not been studied in patients wearing contact lenses.

INDICATIONS AND USAGE
Timolol maleate ophthalmic gel forming solution 0.25% and 0.5% are indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

CONTRAINDICATIONS
Timolol maleate ophthalmic gel forming solution is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease (see WARNINGS); (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure (see WARNINGS); (7) cardiogenic shock; or (8) hypersensitivity to any component of
this product.

WARNINGS
As with many topically applied ophthalmic drugs, this drug is absorbed —— systemically.

The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical ophthalmic administration. For example, severe respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma, and, rarely death in association with cardiac failure, have been reported following systemic or ophthalmic administration of timolol maleate. (See CONTRAINDICATIONS.)

Cardiac Failure
Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardial contractility, and its inhibition by beta-adrenergic receptor blockade may precipitate more severe failure.

In Patients Without a History of Cardiac Failure, continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of cardiac failure, timolol maleate ophthalmic gel forming solution should be discontinued.

Obstructive Pulmonary Disease
Patients with chronic obstructive pulmonary disease (e.g., chronic bronchitis, emphysema) of mild or moderate severity, bronchospastic disease, or a history of bronchospastic disease (other than bronchial asthma or a history of bronchial asthma, in which timolol maleate ophthalmic gel forming solution is contraindicated [see CONTRAINDICATIONS]) should, in general, not receive beta-blockers, including timolol maleate ophthalmic gel forming solution.

Major Surgery
The necessity or desirability of withdrawal of beta-adrenergic blocking agents prior to major surgery is controversial. Beta-adrenergic receptor blockade impairs the ability of the heart to respond to beta-adrenergically mediated reflex stimuli. This may augment the risk of general anesthesia in surgical procedures. Some patients receiving beta-adrenergic receptor blocking agents have experienced protracted, severe hypotension during anesthesia. Difficulty in restarting and maintaining the heartbeat has also been reported. For these reasons, in patients undergoing elective surgery, some authorities recommend gradual withdrawal of beta-adrenergic receptor blocking agents. If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists.
Diabetes Mellitus
Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. Beta-adrenergic receptor blocking agents may mask the signs and symptoms of acute hypoglycemia.

Thyrotoxicosis
Beta-adrenergic blocking agents may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism. Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm.

PRECAUTIONS
General
Because of potential effects of beta-adrenergic blocking agents on blood pressure and pulse, these agents should be used with caution in patients with cerebrovascular insufficiency. If signs or symptoms suggesting reduced cerebral blood flow develop following initiation of therapy with timolol maleate ophthalmic gel forming solution, alternative therapy should be considered.

There have been reports of bacterial keratitis associated with the use of multiple dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface. (see PRECAUTIONS, Information for Patients.)

Choroidal detachment after filtration procedures has been reported with the administration of aqueous suppressant (e.g., timolol) therapy.

Angle-closure glaucoma: In patients with angle-closure glaucoma, the immediate objective of treatment is to reopen the angle. This may require constricting the pupil. Timolol maleate ophthalmic gel forming solution has little or no effect on the pupil and should not be used alone in the treatment of angle-closure glaucoma.

Anaphylaxis: While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reactions to a variety of allergens may be more reactive to repeated accidental, diagnostic, or therapeutic challenge with such allergens. Such patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions.

October 13, 1998
**Muscle Weakness**: Beta-adrenergic blockade has been reported to potentiate muscle weakness consistent with certain myasthenic symptoms (e.g., diplopia, ptosis, and generalized weakness). Timolol has been reported rarely to increase muscle weakness in some patients with myasthenia gravis or myasthenic symptoms.

**Information for Patients**
Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures.

Patients should also be instructed that ocular solutions, if handled improperly, could become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions. (See PRECAUTIONS, General.)

Patients should also be advised that if they have ocular surgery or develop an intercurrent ocular condition (e.g., trauma or infection), they should immediately seek their physician's advice concerning the continued use of the present multidose container.

Patients should be instructed to invert the closed container and shake once before each use. It is not necessary to shake the container more than once.

Patients requiring concomitant topical ophthalmic medications should be instructed to administer these at least 10 minutes before instilling timolol maleate ophthalmic gel forming solution.

Patients with bronchial asthma, a history of bronchial asthma, severe chronic obstructive pulmonary disease, sinus bradycardia, second or third degree atrioventricular block, or cardiac failure should be advised not to take this product. (See CONTRAINDICATIONS.)

Transient blurred vision or visual disturbance, generally lasting from 30 seconds to 5 minutes, following instillation may impair the ability to perform hazardous tasks such as operating machinery or driving a motor vehicle.

**Drug Interactions**
**Beta-adrenergic blocking agents**: Patients who are receiving a beta-adrenergic blocking agent orally and timolol maleate ophthalmic gel forming solution should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. Patients should not usually receive two topical ophthalmic beta-adrenergic blocking agents concurrently.

October 13, 1996
Calcium antagonists: Caution should be used in the co-administration of beta-adrenergic blocking agents, such as timolol maleate ophthalmic gel forming solution, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, or hypotension. In patients with impaired cardiac function, co-administration should be avoided.

Catecholamine-depleting drugs: Close observation of the patient is recommended when a beta blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension.

Digitalis and calcium antagonists: The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time.

Quinidine: Potentiated systemic beta-blockade (e.g., decreased heart rate) has been reported during combined treatment with quinidine and timolol, possibly because quinidine inhibits the metabolism of timolol via the P-450 enzyme, CYP2D6.

Injectable Epinephrine: (See PRECAUTIONS, General, Anaphylaxis)

Carcinogenesis, Mutagenesis, Impairment of Fertility
In a two-year study of timolol maleate administered orally to rats, there was a statistically significant increase in the incidence of adrenal pheochromocytomas in male rats administered 300 mg/kg/day (approximately 42,000 times the systemic exposure following the maximum recommended human ophthalmic dose). Similar differences were not observed in rats administered oral doses equivalent to approximately 14,000 times the maximum recommended human ophthalmic dose.

In a lifetime oral study in mice, there were statistically significant increases in the incidence of benign and malignant pulmonary tumors, benign uterine polyps, and mammary adenocarcinomas in female mice at 500 mg/kg/day (approximately 71,000 times the systemic exposure following the maximum recommended human ophthalmic dose), but not at 5 or 50 mg/kg/day (approximately 700 or 7,000, respectively, times the systemic exposure following the maximum recommended human ophthalmic dose). In a subsequent study in female mice, in which postmortem examinations were limited to the uterus and the lungs, a statistically significant increase in the incidence of pulmonary tumors was again observed at 500 mg/kg/day.
The increased occurrence of mammary adenocarcinomas was associated with elevations in serum prolactin, which occurred in female mice administered oral timolol at 500 mg/kg/day, but not at oral doses of 5 or 50 mg/kg/day. An increased incidence of mammary adenocarcinomas in rodents has been associated with administration of several other therapeutic agents that elevate serum prolactin, but no correlation between serum prolactin levels and mammary tumors has been established in humans.

Furthermore, in adult human female subjects who received oral dosages of up to 60 mg of timolol maleate (the maximum recommended human oral dosage), there were no clinically meaningful changes in serum prolactin.

Timolol maleate was devoid of mutagenic potential when tested in vivo (mouse) in the micronucleus test and cytogenetic assay (doses up to 800 mg) and in vitro in a neoplastic cell transformation assay (up to 100 μg/mL). In Ames tests, the highest concentrations of timolol employed, 5,000 or 10,000 μg/plate, were associated with statistically significant elevations of revertants observed with tester strain TA 100 (in seven replicate assays), but not in the remaining three strains. In the assays with tester strain TA 100, no consistent dose response relationship was observed, and the ratio of test to control revertants did not reach 2. A ratio of 2 is usually considered the criterion for a positive Ames test.

Reproduction and fertility studies in rats demonstrated no adverse effect on male or female fertility at doses up to 21,000 times the systemic exposure following the maximum recommended human ophthalmic dose.

Pregnancy
- Teratogenic effects:
  Pregnancy Category C. Teratogenicity studies with timolol in mice, rats, and rabbits at oral doses up to 50 mg/kg/day (7,000 times the systemic exposure following the maximum recommended human ophthalmic dose) demonstrated no evidence of fetal malformations. Although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring. Doses of 1000 mg/kg/day (142,000 times the systemic exposure following the maximum recommended human ophthalmic dose) were maternotoxic in mice and resulted in an increased number of fetal resorptions. Increased fetal resorptions were also seen in rabbits at doses of 14,000 times the systemic exposure following the maximum recommended human ophthalmic dose, in this case without apparent maternotoxicity.

There are no adequate and well-controlled studies in pregnant women. Timolol maleate ophthalmic gel forming solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Nursing Mothers
Timolol maleate has been detected in human milk following oral and ophthalmic drug administration. Because of the potential for serious adverse reactions from Timolol maleate ophthalmic gel forming solution in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use
Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS
In clinical trials with timolol maleate ophthalmic gel forming solutions, transient blurred vision upon instillation of the drop was reported in approximately one in three patients but was rarely the cause of discontinuation. The frequency of patients reporting burning and stinging upon instillation was approximately one in eight patients which was comparable to that observed for TIMOPTIC.

Adverse experiences reported in 1-5% of patients were:

Ocular: Blepharitis, conjunctivitis, crusting, discomfort, foreign body sensation, hyperemia, pruritus and tearing;

Systemic: Headache, hypertension, and upper respiratory infections.

The following additional adverse experiences have been reported with the ocular administration of this or other timolol maleate formulations:

BODY AS A WHOLE
Asthenia/fatigue and chest pain.

CARDIOVASCULAR
Bradycardia, arrhythmia, hypotension, hypertension, syncope, heart block, cerebral vascular accident, cerebral ischemia, cardiac failure, worsening of angina pectoris, palpitation, cardiac arrest, pulmonary edema, dizziness, edema, claudication, Raynaud’s phenomenon, and cold hands and feet.

DIGESTIVE
Nausea, diarrhea, dyspepsia, anorexia, and dry mouth.

IMMUNOLOGIC
Systemic lupus erythematosus.
NERVOUS SYSTEM/PSYCHIATRIC
Depression, increase in signs and symptoms of myasthenia gravis, paresthesia, somnolence, insomnia, nightmares, behavioral changes and psychic disturbances including confusion, hallucinations, anxiety, disorientation, nervousness, and memory loss.

SKIN
Alopecia and psoriasiform rash or exacerbation of psoriasis.

HYPERSENSITIVITY
Signs and symptoms of systemic allergic reactions, including angioedema, urticaria and localized and generalized rash.

RESPIRATORY
Bronchospasm (predominantly in patients with pre-existing bronchospastic disease), respiratory failure, dyspnea, nasal congestion, and cough.

ENDOCRINE
Masked symptoms of hypoglycemia in diabetic patients (see WARNINGS).

SPECIAL SENSES
Signs and symptoms of ocular irritation including blepharitis, keratitis, and dry eyes; ptosis; decreased corneal sensitivity; cystoid macular edema; visual disturbances including refractive changes and diplopia; pseudopemphigoid; tinnitus and choroidal detachment following filtration surgery (see PRECAUTIONS, General).

UROGENITAL
Retropertoneal fibrosis, decreased libido, impotence and Peyronie's disease.

The following additional adverse effects have been reported in clinical experience with ORAL timolol maleate or other ORAL beta-blocking agents and may be considered potential effects of ophthalmic timolol maleate: Allergic: Erythematous rash, fever combined with aching and sore throat, laryngospasm with respiratory distress; Body as a Whole: Extremity pain, decreased exercise tolerance, weight loss; Cardiovascular: Worsening of arterial insufficiency, vasodilatation; Digestive: Gastrointestinal pain, hepatomegaly, vomiting, mesenteric arterial thrombosis, ischemic colitis; Hematologic: Nonthrombocytopenic purpura, thrombocytopenic purpura, agranulocytosis; Endocrine: Hyperglycemia, hypoglycemia; Skin: Pruritus, skin irritation, increased pigmentation, sweating; Musculoskeletal: Arthralgia; Nervous System/Psychiatric: Vertigo, local weakness, diminished concentration, reversible mental depression progressing to catatonia, an acute reversible syndrome characterized by disorientation for time and place, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometric
tests; *Respiratory:* Rales, bronchial obstruction; *Urogenital:* Urination difficulties.

**OVERDOSEAGE**

No data are available in regard to human overdose with, or accidental oral ingestion of timolol maleate ophthalmic gel forming solution.

There have been reports of inadvertent overdose with timolol maleate ophthalmic solution resulting in systemic effects similar to those seen with systemic beta-adrenergic blocking agents such as dizziness, headache, shortness of breath, bradycardia, bronchospasm, and cardiac arrest (see also ADVERSE REACTIONS).

Overdosage has been reported with Tablets BLOCADREN (timolol maleate tablets). A 30 year old female ingested 650 mg of BLOCADREN (maximum recommended oral daily dose is 60 mg) and experienced second and third degree heart block. She recovered without treatment but approximately two months later developed irregular heartbeat, hypertension, dizziness, tinnitus, faintness, increased pulse rate, and borderline first degree heart block.

An *in vitro* hemodialysis study, using *14C* timolol added to human plasma or whole blood, showed that timolol was readily dialyzed from these fluids; however, a study of patients with renal failure showed that timolol did not dialyze readily.

**DOSAGE AND ADMINISTRATION**

Patients should be instructed to invert the closed container and shake once before each use. It is not necessary to shake the container more than once. Other topically applied ophthalmic medications should be administered at least 10 minutes before timolol maleate ophthalmic gel forming solution (See PRECAUTIONS, Information for Patients).

Timolol maleate ophthalmic gel forming solution is available in concentrations of 0.25%, and 0.5%. The dose is one drop of timolol maleate ophthalmic gel forming solution (either 0.25% or 0.5%) in the affected eye(s) once daily.

Because in some patients the intraocular pressure-lowering response to timolol maleate ophthalmic gel forming solution may require a few weeks to stabilize, evaluation should include a determination of intraocular pressure after approximately 4 weeks of treatment with timolol maleate ophthalmic gel forming solution.

Dosages higher than one drop of 0.5% timolol maleate ophthalmic gel forming solution once daily have not been studied. If the patient's intraocular pressure is still not at a satisfactory level on this regimen, concomitant therapy can be considered.

October 13, 1996
Other topically applied ophthalmic medications should be administered at least 10 minutes before timolol maleate ophthalmic gel forming solution. (See PRECAUTIONS, Information for Patients.)

HOW SUPPLIED
Timolol maleate ophthalmic gel forming solution is a colorless to nearly colorless, slightly opalescent, and slightly viscous solution.

Timolol maleate ophthalmic gel forming solution, 0.25% timolol equivalent, is supplied in plastic DROP-TAINER® dispenser as follows:

NDC 61314-224-25, 2.5 mL
NDC 61314-224-05, 5 mL
NDC 61314-224-26, 3 x 2.5 mL

Timolol maleate ophthalmic gel forming solution, 0.5% timolol equivalent, is supplied in plastic DROP-TAINER® dispenser as follows:

NDC 61314-225-25, 2.5 mL
NDC 61314-225-05, 5 mL
NDC 61314-225-26, 3 x 2.5 mL

Storage
Store between 2° and 25°C (36° and 77°F). Protect from light.

Rx Only

Dist. By:
FALCON OPHTHALMICs, INC.
Fort Worth, Texas 76134 USA

Mfd. By:
ALCOn LABORATORIES, INC.
Forth Worth, Texas 76134 USA

Printed in USA

October 13, 1998
**PRIMARY CONTAINER LABELS, TGFS 0.25%:**

Label Affixed to Each Container

<table>
<thead>
<tr>
<th>Side Panel</th>
<th>Front Panel</th>
<th>Side Panel</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>NDC 61314-224-XX</strong></td>
<td><strong>USUAL DOSAGE:</strong> Read enclosed insert.</td>
</tr>
<tr>
<td><strong>INGREDIENTS:</strong> Each mL Contains:</td>
<td>Timolol Maleate Ophthalmic Gel Forming Solution 0.25%</td>
<td><strong>STORAGE:</strong> Store at 36 °F to 77 °F (2 °C to 25 °C). Do not freeze. Protect from light.</td>
</tr>
<tr>
<td>Active: 2.5 mg of timolol (equivalent to 3.4 mg of timolol maleate). <strong>Preservative:</strong> Benzododecinium Bromide 0.12 mg. <strong>Inactives:</strong> xanthan gum, tromethamine, boric acid, mannitol, polysorbate-80, and purified water.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>For Topical Ophthalmic Use Only</strong></td>
<td><strong>XX mL Sterile</strong></td>
<td><strong>Dist. by:</strong> FALCON OPHTHALMICS, INC. Fort Worth, Texas 76134 USA <strong>Mfd. by:</strong> ALCONE LABORATORIES, INC. Fort Worth, Texas 76134 USA Printed in USA</td>
</tr>
<tr>
<td><strong>Rx Only</strong></td>
<td><strong>FALCON</strong></td>
<td><strong>LOT:</strong> EXP: (Part Number and revision date)</td>
</tr>
</tbody>
</table>

**XX =**
- 25; 2.5 mL size
- 05; 5 mL size
- 26; 3 x 2.5 mL size

October 13, 1998
<table>
<thead>
<tr>
<th>Back Panel</th>
<th>Side Panel</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rx Only</td>
<td><strong>INGREDIENTS:</strong> Each mL Contains: Active: 2.5 mg of timolol (equivalent to 3.4 mg of timolol maleate). <strong>Preservative:</strong> Benzododecinium Bromide 0.12 mg. <strong>Inactives:</strong> xanthan gum, tromethamine, boric acid, mannitol, polysorbate-80, and purified water.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Front Panel</th>
<th>Top Flap</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDC 61314-224-XX</td>
<td>Timolol Maleate Ophthalmic Gel Forming Solution 0.25%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Bottom Flap</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot. Exp: (Part Number and revision date)</td>
</tr>
</tbody>
</table>

**Storage:** Store at 36 °F to 77°F (2 °C to 25 °C). Do not freeze. Protect from light.

**WARNING:** Avoid touching any surface with the dropper tip, as this may contaminate the solution.

**USUAL DOSAGE:** Read enclosed insert.

**For Topical Ophthalmic Use Only**

**Dist. by:** FALCON OPHTHALMICS, INC. Fort Worth, Texas 76134 USA

**Mfd. by:** ALCON LABORATORIES, INC. Fort Worth, Texas 76134 USA

Printed in USA

---

**XX =**
- 25; 2.5 mL size
- 05; 5 mL size
- 26; 3 x 2.5 mL size

October 13, 1998
PRIMARY CONTAINER LABELS, TGFS 0.5%:

Label Affixed to Each Container

<table>
<thead>
<tr>
<th>Side Panel</th>
<th>Front Panel</th>
<th>Side Panel</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NDC 61314-225-XX</td>
<td><strong>USUAL DOSAGE:</strong> Read enclosed insert.</td>
</tr>
<tr>
<td><strong>INGREDIENTS:</strong> Each mL Contains:</td>
<td>Timolol Maleate Ophthalmic Gel Forming Solution 0.5%</td>
<td><strong>STORAGE:</strong> Store at 36 °F to 77 °F (2 °C to 25 °C). Do not freeze. Protect from light.</td>
</tr>
<tr>
<td>Active: 5.0 mg of timolol (equivalent to 6.8 mg of timolol maleate). <strong>Preservative:</strong> Benzododecinium Bromide 0.12 mg. <strong>Inactives:</strong> xanthan gum, tromethamine, boric acid, mannitol, polysorbate-80, and purified water.</td>
<td>For Topical Ophthalmic Use Only</td>
<td><strong>XX mL</strong></td>
</tr>
<tr>
<td>For Topical Ophthalmic Use Only</td>
<td>Sterile</td>
<td><strong>XX mL</strong></td>
</tr>
<tr>
<td>Rx Only</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**XX = 25; 2.5 mL size**
05; 5 mL size
26; 3 x 2.5 mL size

October 13, 1998
<table>
<thead>
<tr>
<th>Back Panel</th>
<th>Side Panel</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rx Only</td>
<td>Contains: Each mL contains 5.0 mg of timolol maleate, 6.8 mg of benzodiazepine, 0.12 mg of inosine, 0.1 mg of benzyl alcohol, 0.05 mg of xanthan gum, 0.1 mg of sodium metabisulfite, 0.05 mg of sodium hydroxide, and purified water.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Front Panel</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDC 61314-225-XX</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Bottom Flap</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot: Exp: (Part Number and revision date)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Top Flap</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timolol Maleate Ophthalmic Gel Forming Solution 0.5%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FALCON</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>USUAL DOSAGE: Read enclosed insert.</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>For Topical Ophthalmic Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Only</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dist. by: FALCON OPHTHALMIC INC.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fort Worth, Texas 76134 USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>UPC Code</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>XX, ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>STERILE FALCON</td>
</tr>
</tbody>
</table>

XX = 25; 2.5 mL size
05; 5 mL size
26; 3 x 2.5 mL size

October 13, 1996